In accordance with this background, we proposed to study the beneficial effects of administering this SDP daily in a one-year, prospective open pilot study with a cohort having a moderate to severe liver fat content (≥17.4%) together with either dyslipidemia, altered hepatic enzymes or ultra-sensitive C-reactive protein (us-CRP), which could relate to a NASH state. This evidence concerns the gene CRP and metabolic dysfunction-associated steatohepatitis.